In patients with IBD, management of immunosuppressive regimens, as well as safety and efficacy of vaccines, has raised many questions during the COVID-19 pandemic.
The decision whether or not to treat patients with portal vein thrombosis is frequently encountered and remains a challenge.
The authors review gut dysfunction and microbiota changes during HIV infection and IBD and discuss how they may induce a dysfunctional mucosal barrier, dysbiosis, and changes on the cellular level, including monocytes, macrophages, and dendritic cells.
C. Andrew Kistler, MD, PharmD, examines existing data about bariatric surgery and the risk for subsequent colorectal cancer development.
A clinician discusses whether inflammatory bowel disease is a risk factor for the development of dementia.